Emerging studies suggest this peptide, a dual agonist targeting both incretin and another hormone, could provide a promising advancement for obesity management . Preliminary human trials have shown considerable reductions in abdominal mass , conceivably surpassing existing weight-loss medications . However , more assessment is necessary to fully… Read More